These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 22337192)

  • 1. Clinical examination: losing the shine.
    Garg PK; Kumar A
    Singapore Med J; 2012 Feb; 53(2):149. PubMed ID: 22337192
    [No Abstract]   [Full Text] [Related]  

  • 2. Umbilical metastatic deposit from recurrent cholangiocarcinoma: F18-FDG PET-CT findings.
    Tan ML; Padhy AK
    Singapore Med J; 2011 Nov; 52(11):e236-8. PubMed ID: 22173264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [18F-FDG-PET-CT in soft tissue sarcomas: when to image?].
    Rodríguez-Alfonso B; Mucientes Rasilla J; Mitjavila Casanovas M; Cardona Arboniés J; Cubedo R
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):43-9. PubMed ID: 24094372
    [No Abstract]   [Full Text] [Related]  

  • 4. PET monitoring of clear cell sarcoma of tendons and aponeuroses.
    Nguyen BD; Roarke MC; Ram PC
    Clin Nucl Med; 2007 May; 32(5):415-7. PubMed ID: 17452880
    [No Abstract]   [Full Text] [Related]  

  • 5. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
    Jadvar H; Henderson RW; Conti PS
    J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
    Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
    PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Not Available].
    Koestner W; Dämmrich M; Derlin T
    Rofo; 2016 Mar; 188(3):300-1. PubMed ID: 26756935
    [No Abstract]   [Full Text] [Related]  

  • 8. Advanced multiple myeloma with negative bone marrow biopsy and positive soft tissue lesions in the (18)F-FDG PET/CT scan.
    Ceneli O; Haznedar R
    Hell J Nucl Med; 2008; 11(1):56-7. PubMed ID: 18392234
    [No Abstract]   [Full Text] [Related]  

  • 9. FDG PET-CT evaluation of granular cell tumor of the soft tissue.
    Hamada K; Fujimoto T; Omori S; Emori M; Joyama S; Nakanishi K; Tomita Y; Naka N; Araki N
    Clin Nucl Med; 2010 Mar; 35(3):192-3. PubMed ID: 20173456
    [No Abstract]   [Full Text] [Related]  

  • 10. F-18 FDG PET/CT imaging of disseminated coccidioidomycosis.
    Nguyen BD
    Clin Nucl Med; 2006 Sep; 31(9):568-71. PubMed ID: 16921289
    [No Abstract]   [Full Text] [Related]  

  • 11. FDG PET/CT for bone and soft-tissue biopsy.
    Nanni C; Gasbarrini A; Cappelli A; Sandler I; Graziani T; Guidalotti P; Golfieri R; Boriani S; Fanti S
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1333-4. PubMed ID: 25693761
    [No Abstract]   [Full Text] [Related]  

  • 12. Added value of PET and PET-computed tomography in oesophageal cancer: a review of current practice.
    Douis H; Jafri M
    Nucl Med Commun; 2008 Sep; 29(9):840. PubMed ID: 18677217
    [No Abstract]   [Full Text] [Related]  

  • 13. F-18 fluorodeoxyglucose positron emission tomography/computed tomography imaging in left thigh intramuscular myxoma.
    Ho L; Wassef H; Henderson R; Seto J
    Clin Nucl Med; 2009 Apr; 34(4):224-5. PubMed ID: 19300052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensity of FDG uptake is not everything: synchronous liposarcoma and fibrous dysplasia in the same patient on FDG PET-CT imaging.
    Charest M; Singnurkar A; Hickeson M; Novales JA; Derbekyan V
    Clin Nucl Med; 2008 Jul; 33(7):455-8. PubMed ID: 18580228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application of fluorine-18 fluorodeoxyglucose-positron emission tomography and positron emission tomography computed tomography in patients with tuberculosis].
    Li D; Lü PX
    Zhonghua Jie He He Hu Xi Za Zhi; 2012 Nov; 35(11):852-4. PubMed ID: 23290043
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical Impact of Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Carried Out for Non-Medicare Eligible Indications in Australia: A Prospective Study.
    Lin P; Stoakes E; Scott A; Sam S; Chicco A
    Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):753-4. PubMed ID: 26345249
    [No Abstract]   [Full Text] [Related]  

  • 17. PET/CT visualises inflammatory activity of pulmonary artery aneurysms in Behçet disease.
    Denecke T; Staeck O; Amthauer H; Hänninen EL
    Eur J Nucl Med Mol Imaging; 2007 Jun; 34(6):970. PubMed ID: 17447060
    [No Abstract]   [Full Text] [Related]  

  • 18. False-positive positron emission tomography in patients with history of malignancy.
    Lindskog DM; Nikkhou K; Talusan P
    J Clin Oncol; 2011 Jul; 29(19):e582-5. PubMed ID: 21502554
    [No Abstract]   [Full Text] [Related]  

  • 19. Fluorodeoxyglucose positron emission tomography/computed tomography in cytologically indeterminate thyroid nodules.
    Sebastianes FM; Pereira MA; Cerci JJ
    Am J Otolaryngol; 2009; 30(4):291-2; author reply 292-3. PubMed ID: 19563946
    [No Abstract]   [Full Text] [Related]  

  • 20. F-18 FDG PET/CT imaging of extramammary Paget disease of the perianal region.
    Niederkohr RD; Gambhir SS
    Clin Nucl Med; 2006 Sep; 31(9):561-3. PubMed ID: 16921286
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.